Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response

Abstract There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy–refractory metastatic osteosarcoma who was successfully treated with the combination of palbociclib (CDK4/6 inhibitor) and lenvatinib (multikinase FGFR inhibi...

Full description

Bibliographic Details
Main Authors: Hanna E. Persha, Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah, Razelle Kurzrock
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Hematology & Oncology
Subjects:
Osteosarcoma
Targeted therapy
Precision
Genomic
Online Access:https://doi.org/10.1186/s13045-022-01344-x

Similar Items

Similar Items